respectively. 7 (4.8%) had a preoperative cervical length (CL) <25mm. All patients elected Solomon FLOC; complete outcome was obtained for 140 pregnancies. Intraoperative intentional septostomy was less frequent in our cohort (7 (5%) vs. 17 (12%); p¼0.024) but rupture of membranes (PPROM) within 2 weeks of FLOC was similar (6 (4%) vs 4 (3%); p¼0.27). PPROM at birth was seen in 26 (18%) (vs. 57 (42%); p<0.005, Table) . Recurrent TTTS (n¼2, 1%) and Twin anemia polycythemia sequence (n¼3, 2%) requiring repeat FLOC was similar to the Solomon-RCT rate. Median FLOC to delivery interval was 78.5 days (0-141) resulting in a delivery gestational age of 32.2 weeks (range 18+5 e 38+0). Pre-FLOC CL was unrelated to the interval to delivery (Pearson 0.12, p¼0,331; median interval 61 vs 82 days for CL<25 and above respectively, p¼0.492). Overall twin survival was significantly higher due to a larger proportion of double twin survival at birth (104 74% vs 87 (64%), p<0.05, Table) . CONCLUSION: Solomon FLOC offered in a clinical setting performs at least as well as anticipated from the randomized trial with superior outcomes compared to any other treatment. In the absence of any absolute contraindication Solomon FLOC should be offered to all TTTS patients irrespective of disease severity. OBJECTIVE: Prenatal diagnosis of critical congenital heart disease (CCHD) has been increasing over the last two decades. While this allows care teams to plan deliveries of infants with CCHD, efforts may result in increasing rates of Cesarean-section delivery. We sought to identify trends in mode of delivery in infants with CCHD over an 18-year period in Texas and compare this to the general population in the state of Texas over the same time period. STUDY DESIGN: We identified live born infants with a diagnosis of CCHD from January 1999 through December 2016 using the Texas Public Use Data File, a population-based administrative database that captures nearly 100% of hospitalizations in the state of Texas. CCHD was defined as congenital heart disease likely to require intervention within the first year of life. Infants with a discharge diagnosis of a multiple gestation birth, significant birth defect or a known genetic abnormality were excluded. We evaluated the proportion of births annually that were delivered via Cesarean over the course of the time period studied. We compared this to the proportion of live births that were delivered via Cesarean in the state of Texas, using data from the Texas Department of State Health Services Vital Statistics Data over the same time period. Cesarean delivery over time in CCHD was evaluated using generalized estimating equations accounting for hospital clustering. The rates of Cesarean delivery were compared between CCHD and Texas data overall using Chi square test and Chi square test for trend. RESULTS: There was a total of 5,961 births fulfilling inclusion criteria. The mean percentage of cesareans performed for infants with CCHD during the study period was 46.1% compared to 32.6% in the overall infant population in Texas (p<0.001). For both groups, there appeared to be a significant yearly increase in the number of cesareans performed for both groups until 2008 (CCHD group mean annual change +1.45%, p¼0.024, and Texas +1.13%, p¼0.003); after this time the number of cesarean sections plateaued in CCHD and has had a mild decline overall (CCHD group mean annual change -0.06%; p¼0.854, and Texas -0.13%, p¼0.031). CONCLUSION: Cesarean delivery occurred more frequently in infants with CCHD than the general population in the state of Texas from 1999-2016. For both groups, the rates of Cesarean delivery increased and then appear to have plateaued. Further study to identify the reason for the higher percentage of cesarean delivery in CCHD is warranted.
Poster Session I ajog.org OBJECTIVE: Fetal cell free DNA (cfDNA) in the maternal circulation is thought to be primarily of placental origin. We sought to determine if fetuses with a low fetal fraction (FF) in the first trimester are more likely to be affected by placental-mediated conditions, primarily low birth weight. STUDY DESIGN: This is a retrospective cohort study of women who had negative cfDNA screening <14 weeks gestation and delivered a viable infant between July 2016 and June 2018 at a single institution. Women with a multiple gestation or abnormal cfDNA screen were excluded. Women who had a non-reportable cfDNA result were included if their re-draw was negative. FF5%ile were considered to have a low FF. The primary outcome was birth weight 10%ile using growth curves generated by Oken et al. Secondary outcomes included birth weight 5%ile, abruption, hypertensive disorder of pregnancy, stillbirth, and a composite outcome. Chi-squared tests were used for comparisons. Multivariable logistic regressions calculated odds ratios for the primary and secondary outcomes, adjusting for maternal age, BMI, gestational age at draw, parity, chronic hypertension, and tobacco use. RESULTS: Of the 2034 women included, the mean FF was 10.0% (SD 3.4%) and a FF<5.3% was considered low (n¼101). For all women, 66.4% had cfDNA testing at 12 weeks gestation, the median BMI was 24.0 (IQR 21.6-27.5), 42.3% were nulliparous, 1.8% had a diagnosis of chronic hypertension, and 0.7% used tobacco. Compared to pregnancies with a higher FF, there was no significant difference in the incidence of birth weight 10%ile in women with a low FF (11.9 vs 8.0%, p¼0.17), though the comparison was limited by small sample size. Among secondary outcomes, birth weight 5%ile and the composite outcome were significantly higher in the low FF group. In the multivariable analysis, low FF was associated with an increased odds of birth weight 10%ile [aOR 2.20 (95%CI 1.12-4.30)], birth weight £5%ile )], and the composite adverse outcome [aOR 1.91 (95%CI 1.10-3.33)]. CONCLUSION: Low FF (5%ile) among women with negative cfDNA results in the first trimester is associated with increased odds of low birth weight, similar to women with a low PAPP-A. Future studies are needed to determine if a low FF should prompt screening for growth restriction given the potential implications of this recommendation.
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